Drug Profile
Research programme: IDO/TDO inhibitors - CanBas
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator University of Shizuoka
- Developer CanBas
- Class Antineoplastics
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Cancer in Japan
- 03 Nov 2017 Early research in Cancer in Japan (unspecified route) (CanBas pipeline, November 2017)